Stil jete

Food and Drug Administration (FDA) authorizes sale of ZYN nicotine pouches in the US

Food and Drug Administration (FDA) authorizes sale of ZYN nicotine pouches in

ZYN becomes the first and only product in this category to be authorized by the U.S. Food and Drug Administration.

The decision, based on scientific evidence, confirms that ZYN nicotine pouches are a less harmful alternative for adult smokers. This decision comes at a time when the FDA has concluded that the sale of these products is consistent with the principles of protecting the public health.

The ZYN nicotine pouches recently authorized by the FDA are marketed in the United States by Swedish Match, which has been part of Philip Morris International since 2022. This authorization is an important step in protecting the public health, given that these products are a better alternative for adult users of traditional cigarettes. After evaluating the scientific evidence, the FDA stated that ZYN brings more benefits than risks to the health of the population. Especially when it comes to adult users who finally quit smoking to switch to ZYN products.

Tom Hyers, President of Swedish Match North America, said: 'About 45 million Americans consume nicotine regularly, approximately 30 million of whom smoke cigarettes, which is the most harmful form of nicotine consumption. The FDA's decision recognizes the role that ZYN can play in protecting public health by helping people quit cigarettes and other traditional tobacco products.'

Philip Morris International: Towards a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company that is actively working to create a smoke-free future and is expanding its portfolio to include products outside the tobacco and nicotine sectors in the long term. The company's current product portfolio consists primarily of cigarettes and smoke-free products. Since 2008, PMI has invested more than $12.5 billion in the development, research and promotion of innovative smoke-free products for adult users who would otherwise continue to smoke. With the aim of completely eliminating cigarette sales.

This includes developing cutting-edge scientific capabilities. Particularly in the areas of preclinical systematic toxicology, clinical research and post-marketing studies. In 2022, PMI acquired Swedish Match, the largest manufacturer of oral nicotine products, becoming a leader in the smokeless category led by the IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has classified IQOS heated devices and Swedish Match snus nicotine pouches as reduced-risk tobacco products. As of June 30, 2024, PMI’s smokeless products are available in 90 markets and PMI estimates that 36.5 million adults worldwide use them. Smokeless products accounted for approximately 38% of PMI’s total net revenue in the first nine months of 2024.

Based on strong foundations and scientific expertise, in February 2021, PMI announced its involvement in the field of well-being and healthcare, making its contribution with the objective of improving lives.